Testosterone Gel (Transdermal): Comprehensive Research Overview

Document Version: 2.0 Last Updated: January 2026 Classification: Research Paper - Hormone Replacement Therapy (Male HRT) Enhancement: Goal Archetype, Age-Stratified Dosing, Drug Interactions, Bloodwork Mapping, Protocol Integration

Goal Relevance:

• Boost energy levels and reduce fatigue associated with low testosterone
• Improve muscle mass and strength for those experiencing muscle loss due to low testosterone
• Enhance libido and sexual function for men with decreased testosterone levels
• Support hormone balance and testosterone optimization for men undergoing hormone replacement therapy
• Aid in recovery from symptoms of hypogonadism, such as low energy and mood swings
• Assist in gender-affirming hormone therapy for individuals seeking masculinization
• Address symptoms of male menopause, such as decreased vitality and mood changes

1. Executive Summary + Regulatory Classification

Overview

Testosterone gel is a clear, transdermal testosterone replacement formulation containing testosterone USP in an alcohol-based hydroalcoholic gel. It is the most widely prescribed testosterone replacement therapy (TRT) in the United States, offering convenient daily application with physiological testosterone levels and minimal "roller-coaster" pharmacokinetics compared to injectable esters.

Chemical Name: Testosterone (17β-hydroxyandrost-4-en-3-one) CAS Number: 58-22-0 Molecular Formula: C₁₉H₂₈O₂ Molecular Weight: 288.42 g/mol

Primary Indications

• FDA-Approved Use: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary hypogonadism [congenital or acquired] and hypogonadotropic hypogonadism [congenital or acquired])
• Off-Label Uses: Gender-affirming hormone therapy (masculinizing therapy), female sexual dysfunction (low-dose compounded formulations)

Regulatory Classification

FDA-Approved Testosterone Gel Products

1. AndroGel 1% - First approved 2000; packets and pump
2. AndroGel 1.62% - Approved 2011; half the volume for same dose
3. Testim 1% - Approved 2002; tube formulation
4. Fortesta 2% - Approved 2010; metered-dose pump; thigh application
5. Vogelxo 1% - Approved 2014; pump, packets, and tubes; AB-rated to Testim

Key Advantages

• Physiological levels: Sustained testosterone concentrations resembling endogenous circadian patterns
• Steady state: Achieved within 48-72 hours
• Lower polycythemia risk: Compared to injectable testosterone
• Convenient: Daily application vs weekly/biweekly injections

Key Disadvantages

• Secondary exposure risk: FDA black box warning for virilization in children
• Skin irritation: Alcohol-based formulation can cause dermatitis
• Transfer prevention measures: Must wash hands, cover site, avoid contact for 2-6 hours
• Cost: More expensive than generic injectable testosterone

2. Chemical Structure & Pharmacology

Molecular Structure

Testosterone USP is a white to practically white crystalline powder, chemically described as 17β-hydroxyandrost-4-en-3-one.

Molecular Formula: C₁₉H₂₈O₂ Molecular Weight: 288.42 g/mol Melting Point: 155°C Solubility: Practically insoluble in water; freely soluble in alcohol, ether, and chloroform

Gel Formulation Composition

AndroGel 1%

• Active ingredient: Testosterone 1% (10 mg/g)
• Inactive ingredients: Carbomer 980, ethanol 67.0%, isopropyl myristate, purified water, sodium hydroxide

AndroGel 1.62%

• Active ingredient: Testosterone 1.62% (16.2 mg/g)
• Inactive ingredients: Carbopol 980, ethyl alcohol, isopropyl myristate, purified water, sodium hydroxide

Testim 1%

• Active ingredient: Testosterone 1% (10 mg/g)
• Unique property: No change in female partner testosterone levels after covering application site with shirt, making it the safest for secondary exposure prevention

Fortesta 2%

• Active ingredient: Testosterone 2% (20 mg/g)
• Application site: Front and inner thighs (first testosterone gel approved for thigh application)
• Delivery: Metered-dose pump (10 mg testosterone per actuation)

Vogelxo 1%

• Active ingredient: Testosterone 1% (10 mg/g)
• Delivery: Pump (12.5 mg per actuation), packets, and tubes
• AB-Rating: Therapeutically equivalent to Testim

Alcohol Content and Permeation Enhancers

All FDA-approved testosterone gels contain ethanol 67.0%, which serves dual purposes:

1. Solvent: Dissolves testosterone and creates gel matrix
2. Permeation enhancer: Increases transdermal absorption by disrupting stratum corneum lipid organization

Additional permeation enhancers include isopropyl myristate, which further enhances skin penetration.

Stability Characteristics

Testosterone in gel formulation remains stable at controlled room temperature (15-30°C) for the duration of the product's shelf life. The alcohol-based vehicle provides antimicrobial preservation.

Goal Archetype Integration

Testosterone gel serves multiple health optimization goals with unique advantages over injectable forms. The transdermal route's distinct pharmacokinetics (steady levels, higher DHT conversion) make it particularly suited to certain patient profiles and objectives.

Primary Goal Alignment

Fat Loss Considerations

Primary Mechanisms:

• Increases basal metabolic rate by enhancing lean mass
• Improves insulin sensitivity, reducing fat storage tendency
• Promotes lipolysis through androgen receptor activation in adipose tissue
• Reduces visceral fat accumulation

Gel-Specific Advantages:

• Steady testosterone levels avoid estradiol spikes that can promote fat retention
• Lower aromatization risk compared to supraphysiological peaks from injections
• Consistent metabolic support without hormonal fluctuations
• Better synergy with GLP-1 agonists for metabolic optimization

Expected Outcomes:

• 3-6% reduction in body fat over 6-12 months (with consistent training/nutrition)
• Preferential loss of visceral over subcutaneous fat
• More gradual but sustained body composition improvement

Muscle Building Considerations

Primary Mechanisms:

• Direct activation of androgen receptors in skeletal muscle
• Increased nitrogen retention and protein synthesis
• Enhanced satellite cell activation

Gel-Specific Characteristics:

• Lower peak testosterone levels compared to injectable cypionate/enanthate
• May result in less dramatic hypertrophy gains than injectable TRT
• Steady anabolic environment without supraphysiological peaks
• Adequate for maintaining muscle mass; may be suboptimal for aggressive building goals

Protocol Considerations:

• Men with primary muscle building goals may prefer injectable TRT for higher peak levels
• Gel appropriate for men seeking muscle maintenance while prioritizing other factors
• Consider twice-daily application or addition of morning dose timing with training

Longevity & Healthspan Considerations

Primary Mechanisms:

• Maintains bone mineral density (reduces fracture risk 30-50%)
• Preserves lean mass (sarcopenia prevention)
• Cognitive protection through neurosteroid effects
• Reduces all-cause mortality in hypogonadal men (observational data)

Gel-Specific Advantages:

• Lower polycythemia risk compared to injectable testosterone - significant longevity advantage
• Physiological, stable levels may be more cardioprotective than roller-coaster kinetics
• TRAVERSE trial demonstrated cardiovascular safety using transdermal 1.62% gel
• Better long-term tolerability profile for decades-long HRT

Expected Outcomes:

• Maintained functional capacity into later decades
• Reduced risk of osteoporotic fractures
• Lower hematocrit-related cardiovascular risk
• Sustained cognitive function and mood stability

When Testosterone Gel Makes Sense

Testosterone gel is the preferred TRT modality when:

• Stable levels prioritized - Patient prefers physiological rhythm without peaks/troughs
• Cardiovascular risk factors present - Lower polycythemia risk favors gel
• Baseline hematocrit elevated (48-50%) - Injectable may push hematocrit too high
• Needle aversion - Patient strongly prefers non-injectable administration
• Cognitive/mood focus - Stable levels optimize neurological effects
• Longevity-focused protocol - Lower adverse event profile for long-term use
• Concurrent GLP-1 therapy - Steady testosterone complements metabolic optimization
• Elderly patients (>65) - More conservative approach with easier monitoring

When to Choose Injectable Instead

Consider injectable testosterone (cypionate/enanthate) when:

• Primary goal is muscle hypertrophy - Higher peak levels more anabolic
• Cost is primary concern - Generic injectable is 5-10x less expensive
• Skin sensitivity/dermatitis - Alcohol-based gels cause significant irritation
• Secondary exposure risk is high - Children or pregnant women in household
• Poor transdermal absorption - Some patients (5-10%) are "non-absorbers"
• Higher testosterone targets needed - Some men need >800 ng/dL for symptom resolution
• Patient prefers weekly/biweekly dosing - Daily application not feasible

3. Mechanism of Action (Tissue-Specific)

Androgen Receptor Binding

Testosterone exerts its effects through binding to the androgen receptor (AR), a nuclear receptor that regulates gene transcription. Upon binding:

1. Receptor activation: Testosterone or dihydrotestosterone (DHT) binds to cytoplasmic AR
2. Nuclear translocation: Hormone-receptor complex translocates to nucleus
3. DNA binding: Complex binds to androgen response elements (AREs) on target genes
4. Transcription: Upregulates or downregulates gene expression

Tissue-Specific Metabolism

Direct testosterone action:

• Muscle tissue (anabolic effects)
• Bone (increased bone mineral density)
• Brain (mood, cognition, libido)
• Adipose tissue (lipolysis)

5α-Reductase conversion to DHT:

• Prostate (growth and secretions)
• Skin (sebaceous gland activity)
• Hair follicles (androgenic alopecia, body hair growth)
• External genitalia

Aromatase conversion to estradiol:

• Bone (epiphyseal closure, bone density)
• Adipose tissue
• Brain (neuroprotection, mood regulation)
• Breast tissue (gynecomastia at high levels)

Physiological Effects

Anabolic effects:

• Increased muscle mass and strength
• Increased bone mineral density
• Stimulation of linear growth (pre-epiphyseal closure)
• Increased red blood cell production (erythropoiesis)

Androgenic effects:

• Development and maintenance of male secondary sexual characteristics
• Spermatogenesis
• Deepening of voice
• Growth of facial, axillary, and pubic hair
• Sebaceous gland activity

Metabolic effects:

• Decreased fat mass (visceral and subcutaneous)
• Improved insulin sensitivity
• Increased basal metabolic rate

Neurological effects:

• Improved mood and sense of well-being
• Increased libido
• Enhanced cognitive function (spatial reasoning, memory)

4. Pharmacokinetics & Formulation Comparison

Absorption

Transdermal absorption characteristics:

• Absorption continues for the entire 24-hour dosing interval
• Approximately 9-14% of applied testosterone is systemically absorbed
• Remaining 86-91% remains on skin surface or is washed off

Time to peak levels:

• Mean peak testosterone levels achieved 4 hours after initial application
• Sustained elevation for up to 18 hours after application

Time to steady state:

• Steady state achieved within 48-72 hours of first application
• Median time to steady-state: 1.1 days (95% CI, 0.7–3.4 days)
• Serum concentrations approximate steady state by end of first 24 hours

Distribution

Protein binding:

• 98% bound to sex hormone-binding globulin (SHBG, 40-50%) and albumin (48-58%)
• 2% circulates as free (bioactive) testosterone

Volume of distribution:

• Approximately 1.0 L/kg

Metabolism

Primary metabolites:

• Dihydrotestosterone (DHT): via 5α-reductase; 2.5× more potent at AR
• Estradiol (E2): via aromatase enzyme (CYP19A1)
• Androsterone and etiocholanolone: inactive metabolites excreted in urine

Elimination half-life:

• 10-100 minutes for free testosterone (shorter than injectable esters)
• Continuous absorption from skin depot maintains levels

Excretion:

• Urine: 90% as glucuronide and sulfate conjugates
• Feces: 6%

Formulation Comparison: Testim vs AndroGel

A pivotal pharmacokinetic study comparing Testim and AndroGel found significant differences:

Clinical interpretation: The two gels are not bioequivalent; Testim may have superior pharmacokinetic properties. However, both formulations achieve therapeutic testosterone levels when properly dosed.

Application Site Absorption Comparison

Studies comparing absorption across different body sites found:

Best absorption:

• Arms/shoulders achieve highest testosterone levels
• Axilla (underarm): Double the Cmax compared to inner arm

Application site characteristics:

• Shoulders/deltoid: Consistent absorption, easy to reach, large surface area
• Upper arms: Thin skin, good vascularity, moderate hair density
• Abdomen: Large surface area, good blood flow, but variable hair coverage
• Inner thighs: Thin skin, highly vascularized, less hair, good for Fortesta

Product-specific recommendations:

• Testim: Arms/shoulders only
• AndroGel 1%: Shoulders, upper arms, or abdomen
• AndroGel 1.62%: Shoulders and upper arms only (NOT abdomen, penis, scrotum, chest, armpits, or knees)
• Fortesta: Front and inner thighs

5. Clinical Dosing Guidelines (FDA-Labeled + Off-Label)

FDA-Approved Dosing

AndroGel 1%

Starting dose: 50 mg testosterone applied once daily in the morning

Dose adjustment:

• Measure serum testosterone at Day 14 and Day 28
• If below normal range: Increase to 75 mg daily, then 100 mg if needed
• If above normal range: Decrease dose or discontinue
• Available doses: 25 mg, 50 mg, 75 mg, 100 mg

Treatment outcomes: 87% of appropriately titrated patients achieved average serum testosterone within normal range by Day 180

AndroGel 1.62%

Starting dose: 40.5 mg testosterone (two pump actuations) once daily in the morning

Dose adjustment:

• Measure predose morning testosterone at Day 14 and Day 28
• If below normal range: Increase to 60.75 mg (three pumps), then 81 mg (four pumps) if needed
• If above normal range: Decrease to 20.25 mg (one pump) or discontinue
• Available doses: 20.25 mg, 40.5 mg, 60.75 mg, 81 mg

Efficacy: 78% (106/136) of men had average testosterone in normal range at Day 364

Testim 1%

Starting dose: 50 mg testosterone (one tube) once daily in the morning

Dose adjustment:

• If below normal range: Increase to 100 mg daily
• Available doses: 50 mg, 100 mg

Fortesta 2%

Starting dose: 40 mg testosterone (four pump actuations) once daily in the morning

Dose adjustment:

• Each pump actuation delivers 10 mg testosterone
• Dose range: 10 mg to 70 mg daily
• Titrate based on serum testosterone levels

Vogelxo 1%

Starting dose: 50 mg testosterone once daily in the morning

Dose adjustment:

• Maximum dose: 100 mg once daily
• Pump delivers 12.5 mg per actuation

Monitoring and Titration Protocol

According to the American Urological Association guidelines:

Initial monitoring:

• Testosterone measured at 14 days and 28 days after treatment initiation
• Some formulations: Day 14 and Day 35

Target testosterone levels:

• Goal range: 400-700 ng/dL (mid-normal range)
• Measurements taken as predose morning levels (before daily application)

Long-term monitoring:

• Testosterone levels every 6-12 months while on therapy
• Hematocrit monitored prior to and periodically during treatment

Off-Label Dosing: Gender-Affirming Hormone Therapy

For masculinizing therapy in transgender men:

Transdermal testosterone gel:

• Starting dose: 25-50 mg daily
• Maintenance dose: 50-100 mg daily
• Goal testosterone: 400-700 ng/dL (male physiological range)

Age-Stratified Dosing for Transdermal Testosterone

Transdermal absorption characteristics, skin thickness, and metabolic factors vary by age, requiring tailored dosing approaches.

Age-Specific Transdermal Considerations

Young Adults (20-35):

• Skin absorption typically excellent; may achieve therapeutic levels with lower doses
• If fertility preservation desired, consider HCG co-administration or alternative therapies
• Gel may be suboptimal for aggressive muscle-building goals (consider injectable if priority)
• Verify true hypogonadism with repeat testing before initiating TRT

Middle Age (35-50):

• Peak candidate population for transdermal testosterone
• Steady levels support cognitive function, mood stability during demanding life stage
• Monitor for skin site reactions; rotate application sites if irritation develops
• Good candidates for gel if needle-averse or prioritizing steady hormone environment

Older Adults (50-65):

• TRAVERSE trial enrolled men 45-80 years and demonstrated CV safety
• Lower polycythemia risk of gel particularly advantageous as baseline Hct tends higher
• PSA monitoring every 6 months initially; annually once stable
• Skin thinning with age may cause absorption variability; consider higher-concentration gels (1.62%, 2%) for more consistent delivery

Elderly (65+):

• Start with conservative doses (25-40.5 mg/day)
• Gel's lower erythrocytosis risk makes it preferred over injectable in this population
• Monitor for fluid retention, blood pressure elevation
• Consider application timing to avoid bathing/swimming restrictions
• Increased fall risk if transferring to partners - emphasize transfer prevention protocols

Transdermal Absorption Factors by Age

Clinical Pearl: Approximately 9-14% of applied testosterone is systemically absorbed; this percentage may decrease with age-related skin changes. Dose titration based on serum levels at Day 14 and 28 is essential regardless of age.

Dosing Adjustments for Special Populations

Elderly (≥65 years):

• Start at lower end of dosing range (25-50 mg)
• Monitor for increased cardiovascular and prostate risks
• Gel preferred over injectable due to lower polycythemia risk

Obesity:

• May require higher doses due to increased aromatase activity
• Abdominal application may be suboptimal (increased adiposity reduces absorption)
• Consider shoulder/upper arm application sites
• Target same testosterone levels (400-700 ng/dL)
• Higher DHT:E2 ratio with gel may be advantageous (less estrogen conversion)

Renal impairment:

• No dose adjustment required (testosterone metabolized hepatically)

Hepatic impairment:

• Use with caution; may have altered testosterone metabolism

High Baseline Hematocrit (48-50%):

• Gel strongly preferred over injectable
• Start conservative (40.5 mg/day) and titrate slowly
• Monitor Hct every 4-6 weeks initially
• Target lower testosterone range (400-500 ng/dL) to minimize erythropoietic stimulation

6. Pivotal Clinical Trials & Evidence

TRAVERSE Trial (2023) - Cardiovascular Safety

The TRAVERSE trial was the largest cardiovascular safety study of testosterone replacement therapy ever conducted, mandated by the FDA in 2015.

Study design:

• N = 5,246 men (45-80 years old)
• Intervention: Daily transdermal 1.62% testosterone gel vs placebo gel
• Duration: Mean 22 months (range: up to 5 years)
• Population: Hypogonadism (two testosterone levels <300 ng/dL) with preexisting or high cardiovascular disease risk

Primary endpoint:

• Major adverse cardiac events (MACE): nonfatal MI, nonfatal stroke, or death from cardiovascular causes

Results:

• Testosterone was noninferior to placebo for MACE incidence
• No increased cardiovascular risk with testosterone therapy

FDA action:

• March 2025: FDA recommended removing black box warning for cardiovascular risk
• New warning added for blood pressure increases with testosterone

Venous thromboembolism (VTE):

• Increased incidence of VTE with testosterone, including DVT and pulmonary embolism
• FDA mandated warning label for VTE risk

AndroGel 1.62% Pivotal Efficacy Study

Two-phase, 364-day controlled clinical study:

Phase 1 (182 days):

• N = 234 hypogonadal men on AndroGel 1.62%
• N = 40 on placebo
• Multi-center, randomized, double-blind, placebo-controlled

Phase 2 (182 additional days):

• Open-label extension

Results:

• 78% (106/136) achieved normal testosterone at Day 364
• Well-tolerated with adverse events similar to other testosterone formulations

Testosterone Gel vs Injectable Comparison Studies

Comparative study of testosterone formulations (N = multiple cohorts):

Polycythemia risk:

• Testosterone gel: Lower risk compared to injectable
• Short-acting injectable testosterone: Greater risk of erythrocytosis

Cardiovascular outcomes:

• Testosterone injections associated with greater risk of cardiovascular events, hospitalizations, and deaths compared to gels

Musculoskeletal benefits:

• Intramuscular TRT produced 8% increase in lumbar spine BMD
• Transdermal TRT produced no significant BMD increases
• Higher doses typically administered via IM injection account for difference

Long-Term Pharmacokinetic Stability

180-day study evaluating testosterone gel stability:

Results:

• Pharmacokinetic parameters for total and free testosterone very similar on Days 30, 90, and 180
• Mean steady-state testosterone levels remained stable over 180 days

7. Safety Profile + Black Box Warnings

FDA Black Box Warning: Secondary Exposure to Testosterone

All testosterone gel products carry a boxed warning:

Virilization has been reported in children who were secondarily exposed to testosterone gel. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel. Healthcare providers should advise patients to strictly adhere to recommended instructions for use.

Cases reported to FDA:

• May 2009: FDA issued safety alert after 8 reports of children experiencing adverse effects
• All gel and solution products (AndroGel, Fortesta, Testim, Vogelxo) carry this warning

Signs and symptoms in children:

• Enlargement of penis or clitoris
• Development of pubic hair
• Increased erections and libido
• Aggressive behavior
• Advanced bone age

Reversibility:

• Most signs regressed with removal of testosterone exposure
• In a few cases, enlarged genitalia did not fully return to age-appropriate size

Signs in women:

• Development of acne
• Changes in body hair distribution
• Other signs of virilization
• Menstrual irregularity

Prevention measures:

• Wash hands thoroughly with soap and water after application
• Cover application site with clothing after gel dries
• Avoid swimming or showering for at least 5 hours after application
• Wash application site before anticipated contact with others

Common Side Effects (>5% Incidence)

Dermatological:

• Application site reactions (erythema, pruritus, irritation): 5-37%
• Acne: 1-8%
• Dry skin

Endocrine/Metabolic:

• Gynecomastia: 1-3%
• Increased estradiol levels

Urogenital:

• Prostate-specific antigen (PSA) elevation
• Benign prostatic hyperplasia (BPH) symptoms
• Testicular atrophy (from suppressed LH/FSH)

Hematological:

• Polycythemia/erythrocytosis: 3-18%
• Increased hemoglobin and hematocrit

Other:

• Headache
• Mood changes
• Increased libido

Serious Adverse Events

Polycythemia and Cardiovascular Risk

Men undergoing testosterone replacement therapy have 315% greater risk for developing erythrocytosis.

Critical finding: Developing polycythemia while on testosterone therapy is an independent risk factor for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in the first year of therapy.

Intervention threshold:

• Hematocrit ≥54%: Interrupt therapy, consider phlebotomy, restart at lower dose when hematocrit normalizes

Blood Pressure Elevation

FDA is requiring addition of warnings about increased blood pressure:

• Testosterone can increase blood pressure
• Increased blood pressure can increase cardiovascular risk over time
• Monitor blood pressure during therapy

Venous Thromboembolism (VTE)

FDA mandated warning label for VTE risk:

• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Increased incidence observed in TRAVERSE trial

Flammability Risk

All alcohol-based gels are flammable:

• Avoid fire, flame, or smoking until gel has dried
• Contains ethanol 67.0%
• Avoid exposure to heat

8. Formulation Options & Administration

FDA-Approved Brand Formulations

Generic Formulations

Generic testosterone gel 1% is available from multiple manufacturers at lower cost than brand products. Bioequivalence to branded formulations varies.

Compounded Testosterone Formulations

Compounding pharmacies offer customized testosterone formulations:

Concentration options:

• 0.5% to 20% testosterone
• Custom dosing for individual needs

Base options:

• Alcohol-based gels: Fast drying but may irritate sensitive skin
• Creams: Smooth and moisturizing with less irritation
• Liposomal creams: Encapsulated testosterone in lipid vesicles for enhanced penetration
• Atrevis™ Hydrogel base: Independent testing showed superior testosterone delivery

Regulatory status:

• Prepared pursuant to individually written prescription under Section 503A of Federal Food, Drug, and Cosmetic Act
• No compounded medications reviewed by FDA for safety or efficacy
• Uses USP-grade active pharmaceutical ingredient

Application Technique

Step-by-step procedure:

1. Timing: Apply once daily in the morning to mimic circadian testosterone rhythm
2. Skin preparation: Apply to clean, dry, intact skin
3. Application site: Product-specific (see table above)
4. Application method:
   • Squeeze gel from packet or pump into palm
   • Apply thin layer to application site
   • Spread evenly over entire application area
   • DO NOT apply to genitals (poor absorption, irritation risk)
5. Hand washing: Wash hands thoroughly with soap and water immediately after application
6. Drying time: [Allow gel to dry for 3-5 minutes before dressing](https://www.cleveland clinic.org/health/drugs/18661-testosterone-skin-gel)
7. Covering site: Cover with clothing after drying to prevent transfer
8. Waiting period: Avoid swimming or showering for at least 5 hours

Transfer Prevention Strategies

Methods to prevent secondary exposure:

1. Hand washing: Immediately after application
2. Site coverage: Wear shirt or clothing over application site
3. Shower before contact: Wash application site 5-6 hours after application if physical contact anticipated
4. Time separation: Apply gel at night if morning contact is unavoidable
5. Alternative site: Use thigh application (Fortesta) for lower transfer risk

9. Storage & Stability

Storage Requirements

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F), corresponding to USP Controlled Room Temperature.

Additional requirements:

• Protect from heat and light
• Do not freeze
• Keep out of reach of children
• Discard product after expiration date

Flammability Precautions

This medication is flammable:

• Avoid exposure to heat, fire, flame, and smoking until gel has dried
• Do not apply near open flame or heat source
• Do not smoke while applying or before gel dries

Stability After Opening

Pump formulations:

• Prime pump before first use (3-4 actuations)
• Stable for duration of product shelf life after opening
• Track number of doses remaining (pumps have fixed number of actuations)

Packet formulations:

• Single-use packets
• Use entire contents immediately after opening
• Do not save partial packets for later use

10. Detailed Regulatory Status (FDA, DEA, WADA, International)

FDA Approval History

DEA Schedule III Classification

Testosterone is classified as a Schedule III controlled substance under the Anabolic Steroids Control Act of 1990.

Schedule III criteria:

• Moderate to low potential for physical and psychological dependence
• Medical use accepted in United States

Prescribing restrictions:

• Prescriptions cannot be filled or refilled more than 6 months after issuance
• Maximum 5 refills per prescription
• Electronic prescribing of controlled substances (EPCS) required
• Prescription Drug Monitoring Program (PDMP) reporting mandatory

Healthcare provider requirements:

• DEA registration required to prescribe Schedule III substances
• Stricter oversight from prescribers and pharmacies
• Documentation and recordkeeping requirements

WADA Prohibited Status

Testosterone is prohibited at all times by the World Anti-Doping Agency (WADA).

Classification:

• Anabolic agents (S1)
• All esters and formulations of testosterone are prohibited

Rationale for prohibition: Testosterone meets two of three WADA criteria:

1. Potential to enhance sport performance
2. Represents health risk to athlete
3. Violates spirit of sport

Therapeutic Use Exemption (TUE):

• Athletes can receive permission through TUE for medically necessary testosterone replacement
• Requires documented hypogonadism diagnosis
• Subject to approval by anti-doping authorities

International Regulations

Canada:

• Prescription required
• Listed as Schedule IV controlled substance

United Kingdom:

• Prescription-only medicine (POM)
• Class C controlled drug under Misuse of Drugs Act 1971

Australia:

• Schedule 4 prescription medicine
• Therapeutic Goods Administration (TGA) approved

European Union:

• Prescription required in all EU member states
• Regulated under individual national drug agencies

11. Product Cross-Reference (Compounding vs Brand)

Brand Name Products: Cost Comparison

Prices are estimates and vary by pharmacy, insurance, and location. Updated December 2024.

Compounded Testosterone: Cost and Quality

Typical pricing:

• Testosterone cream 10% (60g): $50-100 (1-3 month supply)
• Testosterone gel 5% (30mL): $40-80 (1 month supply)
• Cost per day: $1-3

Cost advantage: 5-10× less expensive than brand-name products

Quality considerations:

• No FDA review for safety or efficacy
• Quality dependent on pharmacy standards and USP ingredient sourcing
• Variable potency between batches and pharmacies
• Advanced delivery systems (Atrevis™) may enhance absorption

When to consider compounding:

• Cost-prohibitive brand products
• Unique dosing requirements not available commercially
• Sensitivity to brand formulation ingredients (alcohol, preservatives)
• Need for custom base (cream vs gel)

When to avoid compounding:

• Insurance covers brand products
• Consistency and FDA oversight important to patient
• Legal/athletic testing situations requiring standardized products

Injectable Testosterone Comparison

12. References & Citations

FDA Labeling and Approval Documents

1. AndroGel (testosterone) 1% gel label - FDA
2. AndroGel 1.62% - FDA
3. AndroGel 1% - FDA 2025 labeling
4. AndroGel 1.62% - FDA 2025 labeling
5. Testim 1% - FDA 2025 labeling
6. Testim 1% - FDA 2009 black box warning
7. Fortesta 2% - FDA 2025 labeling
8. Fortesta 2% - FDA 2010 approval letter
9. Vogelxo 1% - FDA 2019 labeling
10. AndroGel 1.62% NDA approval summary - FDA

Clinical Pharmacology and Pharmacokinetics

11. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men - PubMed
12. Pharmacokinetics of testosterone after percutaneous gel or buccal administration - PubMed
13. Comparison of steady-state pharmacokinetics of transdermal testosterone patch vs gel - PubMed
14. Pharmacokinetics of testosterone after percutaneous gel - ScienceDirect
15. Pharmacokinetics of testosterone 2% gel - Nature
16. Long-Term Pharmacokinetics of Transdermal Testosterone Gel - Oxford Academic
17. Evaluation of pharmacokinetic profiles: Testim vs AndroGel - PubMed

Clinical Trials and Efficacy Studies

18. TRAVERSE Trial - Cardiovascular Safety of Testosterone - NEJM
19. TRAVERSE Study Supports CV Safety - Cleveland Clinic
20. Comparison of testosterone gel, injections, and pellets - PMC
21. Safety and efficacy of testosterone gel in male hypogonadism - PMC
22. Injection vs transdermal testosterone in older men - PMC
23. Testosterone Gel vs Injection - UPGUYS
24. Study finds gels and patches safer than injections - Fierce Pharma

Safety Profile and Adverse Events

25. FDA Drug Safety Communication: cardiovascular risk - FDA
26. FDA recommends removing CV black box warning - Healio
27. FDA warns about blood clot risk - Harvard Health
28. Testosterone use causing erythrocytosis - PMC
29. Erythrocytosis and Polycythemia Secondary to TRT - ScienceDirect
30. Polycythemia increases MACE/VTE risk - Journal of Urology
31. FDA side effects update: blood pressure risk - MedShadow

Secondary Exposure and Transfer Risk

32. Secondary exposure to testosterone gels - Taylor & Francis
33. Preventing secondary exposure with Nestorone/Testosterone gel - PMC
34. FDA: Kids at risk from testosterone gel - NBC News

Application Site Absorption Studies

35. Absorption of Testim from three application sites - PubMed
36. Absorption of Testosterone Gel from three sites - Wiley
37. Application site affects pharmacokinetics: axilla vs inner arm - ScienceDirect

Product Comparisons and Formulations

38. Comparison of Testosterone Replacement Therapy - BYU Scholars
39. AndroGel vs Testim Comparison - Drugs.com
40. Testim 1% for male hypogonadism - ScienceDirect
41. A new 2% testosterone gel formulation - Wiley

Compounding Pharmacy Resources

42. Compounded Testosterone Cream - Empower Pharmacy
43. Testosterone 5% Gel - Bayview Pharmacy
44. Compounded Testosterone - Harbor Compounding
45. Testosterone Gel (Atrevis) - FormulateRx

Dosing and Clinical Guidelines

46. Dosing Information for AndroGel 1.62% - AndroGel.com
47. Review of Testosterone Therapy Options - US Pharmacist
48. Testosterone Deficiency Guideline - AUA
49. Testosterone transdermal dosing - Medscape
50. Masculinizing hormone therapy guidelines - UCSF

Regulatory and Controlled Substance Information

51. DEA Controlled Substance Schedules
52. Why is testosterone a controlled substance? - Plume
53. Controlled Substances & CSA Schedule Lists - Drugs.com

WADA and Athletic Performance

54. The Prohibited List - WADA
55. List of drugs banned by WADA - Wikipedia
56. Understand the Prohibited List - Athletics Integrity Unit
57. Review of WADA Prohibited Substances - PMC
58. Therapeutic use exemption - Wikipedia

Product-Specific Information

59. Abbott receives FDA approval for AndroGel 1.62% - FierceBiotech
60. Endo receives FDA approval for Fortesta - Endo Investor Relations
61. Vogelxo receives AB-rating to Testim - PR Newswire
62. Vogelxo FDA Approval History - Drugs.com

Drug Interactions

63. Testosterone Interactions Checker - Drugs.com
64. Drug Interactions between testosterone and warfarin - Drugs.com

13. Monitoring & Lab Values

Pre-Treatment Baseline Testing

Required before initiating testosterone gel:

1. Serum testosterone (total):

   • Two morning samples (7-11 AM) on separate days
   • Diagnosis threshold: <300 ng/dL
   • Confirms hypogonadism diagnosis

2. Complete blood count (CBC):

   • Baseline hemoglobin: Normal 13.5-17.5 g/dL
   • Baseline hematocrit: Normal 38-50%
   • Identifies pre-existing polycythemia

3. Prostate-specific antigen (PSA):

   • Baseline PSA (men ≥40 years)
   • Normal: <4.0 ng/mL
   • Abnormal PSA or palpable prostate nodule requires urology evaluation before TRT

4. Digital rectal exam (DRE):

   • Men ≥40 years
   • Assess for prostate abnormalities

5. Lipid panel:

   • Total cholesterol, LDL, HDL, triglycerides
   • Testosterone may alter lipid profile

6. Liver function tests:

   • ALT, AST, bilirubin
   • Baseline hepatic function

On-Treatment Monitoring Schedule

Testosterone Levels

Initial titration phase:

• Measure predose morning testosterone at Day 14 and Day 28 after starting therapy
• Target range: 400-700 ng/dL (mid-normal physiological range)
• Adjust dose based on results

Long-term monitoring:

• Testosterone levels every 6-12 months
• Maintain target 400-700 ng/dL

Hematocrit Monitoring (CRITICAL)

Frequency:

• Baseline, then every 3 months for first year
• Every 6-12 months thereafter if stable

Action thresholds:

• Hematocrit 50-54%: Monitor more frequently, consider dose reduction
• Hematocrit ≥54%: INTERRUPT therapy, consider phlebotomy, restart at lower dose when normalized
• Hemoglobin >17.5 g/dL: Equivalent concern

Rationale: Polycythemia during TRT increases MACE/VTE risk 5-fold in first year

Prostate Monitoring

PSA:

• Baseline, then 3-6 months after starting, then annually
• Concerning changes:
  • PSA increase >1.4 ng/mL in first year
  • PSA >4.0 ng/mL
  • Rapid velocity increase
• Refer to urology for concerning changes

DRE:

• Annually in men ≥40 years
• More frequently if abnormalities detected

Blood Pressure

• Every visit (FDA warning for blood pressure elevation)
• Home monitoring recommended
• Target: <130/80 mmHg

Lipid Panel

• 6-12 months after starting therapy, then annually
• Testosterone may decrease HDL, increase LDL in some patients

Liver Function Tests

• 6-12 months, then annually
• Topical testosterone has minimal hepatotoxicity (unlike oral 17α-alkylated androgens)

Symptoms Monitoring

Patient-reported outcomes:

• Libido, erectile function (validated questionnaires: IIEF-5, SHIM)
• Energy levels, mood, sense of well-being
• Muscle mass and strength
• Application site reactions

Adverse event screening:

• Gynecomastia, nipple tenderness
• Acne or oily skin
• Sleep apnea symptoms (snoring, daytime somnolence)
• Lower urinary tract symptoms (LUTS)
• Edema

Bloodwork Impact Mapping

This section details the expected changes in laboratory markers with transdermal testosterone therapy, with emphasis on gel-specific pharmacokinetic effects including the characteristically higher DHT conversion seen with transdermal delivery.

Expected Marker Changes with Testosterone Gel

Transdermal-Specific: DHT Elevation

Why gel produces more DHT:

• Skin contains high concentrations of 5α-reductase enzyme
• Transdermal delivery results in first-pass conversion to DHT in skin
• DHT levels typically 30-40% higher with gel vs injectable at equivalent testosterone levels

DHT:T Ratio Comparison:

Clinical Implications of Higher DHT:

When Higher DHT is Advantageous:

• Primary goal is libido optimization
• History of gynecomastia on injectable (DHT is anti-estrogenic)
• Desire to minimize estradiol-related side effects
• Older patients who benefit from neurological DHT effects

When Higher DHT is Concerning:

• Family history of aggressive androgenic alopecia
• Active BPH with LUTS symptoms
• History of androgenic side effects (severe acne)
• PSA elevation concerns

Transdermal-Specific: Estradiol (E2) Profile

Why gel produces less estradiol spikes:

• No supraphysiological testosterone peaks that drive aromatization
• Steady testosterone levels result in steady, physiological E2
• Lower peak T levels = lower peak E2 levels

E2 Management with Gel:

• Less often requires aromatase inhibitor compared to injectable
• If E2 elevated, consider:
  1. Weight loss (reduces aromatase activity)
  2. DIM or calcium D-glucarate (estrogen metabolism support)
  3. Low-dose anastrozole only if symptomatic AND labs confirm elevation

Target E2 Range:

• 20-35 pg/mL (optimal range for most men)
• Avoid <15 pg/mL (joint pain, mood issues, bone loss)

• 50 pg/mL may cause gynecomastia, water retention

Hematocrit: The Gel Advantage

Testosterone gel produces significantly lower polycythemia risk than injectable testosterone:

Why the difference:

• Supraphysiological testosterone peaks from injection strongly stimulate erythropoietin
• Gel's steady-state pharmacokinetics produce less EPO stimulation
• Lower peak testosterone = lower peak erythropoietic drive

Monitoring Schedule with Gel

Red Flags in Labs

Labs + Symptoms Integration

14. Drug Interactions & Contraindications - Comprehensive

This section covers all TRT-relevant drug interactions plus transdermal-specific considerations. Testosterone gel shares core interactions with injectable testosterone but has unique considerations related to absorption, transfer risk, and pharmacokinetics.

Prescription Medication Interactions

Anticoagulants

Transdermal-Specific Note: Gel's steady testosterone levels (without supraphysiological peaks) may result in more predictable warfarin interaction compared to injectable; however, INR monitoring protocol remains same.

Diabetes Medications

Clinical Note: Testosterone's metabolic benefits develop over 3-6 months. Proactive diabetes medication adjustments prevent hypoglycemia.

Cardiovascular Medications

Thyroid Medications

Psychiatric Medications

Pain and Anti-inflammatory Medications

Hormone-Modifying Medications

Transdermal-Specific Interactions

Skin and Topical Products

Transfer Risk Interactions

Supplement Interactions

Food and Timing Interactions

Absolute Contraindications

Testosterone gel is contraindicated in:

1. Men with carcinoma of the breast or known or suspected prostate cancer

   • Testosterone may stimulate growth of androgen-responsive tumors
   • Prostate cancer diagnosis must be excluded before TRT

2. Women who are pregnant or may become pregnant

   • Testosterone may cause fetal harm and virilization of female fetus
   • Category X medication

3. Women who are breastfeeding

   • Transfer to infant via breast milk
   • Risk of virilization in female infants

Relative Contraindications (Use with Caution)

Benign prostatic hyperplasia (BPH) with severe symptoms:

• Testosterone may worsen urinary obstruction
• Monitor LUTS closely

Severe heart failure (NYHA Class III-IV):

• Fluid retention risk
• Increased cardiovascular workload

Severe sleep apnea:

• Testosterone may worsen sleep apnea
• Consider sleep study before initiating TRT

Polycythemia (hematocrit >50%):

• Pre-existing polycythemia must be resolved before TRT
• Testosterone will worsen erythrocytosis

Severe liver disease:

• Altered testosterone metabolism
• Use with caution and monitor liver function

Special Populations

Pediatric Use

• Not indicated for use in pediatric populations
• Risk of premature epiphyseal closure
• Risk of virilization in children
• Secondary exposure risk from testosterone gel

Geriatric Use (≥65 years)

• Increased risk of:
  • Prostate cancer
  • Cardiovascular events
  • Polycythemia
  • Sleep apnea exacerbation
• Start at lower doses (25-50 mg daily)
• More frequent monitoring required

Renal Impairment

• No dose adjustment required
• Testosterone metabolized hepatically, not renally

Hepatic Impairment

• Use with caution
• May have altered testosterone metabolism and clearance
• Monitor liver function tests regularly

Protocol Integration

This section addresses when to choose testosterone gel versus injectable formulations, stacking considerations with other optimization compounds, and integration with lifestyle factors.

Gel vs Injectable: Clinical Decision Framework

Stacking with Other Compounds

Testosterone Gel + GLP-1 Agonist Stack

Testosterone Gel + GH Secretagogue Stack (Ipamorelin/CJC-1295)

Testosterone Gel + MK-677 Stack

Testosterone Gel + Healing Peptides (BPC-157, TB-500)

Common TRT Adjuncts with Gel

Timing Considerations

Integration with Lifestyle Pillars

Nutrition Integration

Activity Integration

Sleep Integration

Switching Between Formulations

Switching from Injectable to Gel

Reasons to switch injectable to gel:

• Polycythemia concerns (Hct persistently >50%)
• Desire for more stable mood/energy
• E2 management difficulties
• Partner concerns about injection technique
• Travel considerations

Switching from Gel to Injectable

Reasons to switch gel to injectable:

• Poor absorption (non-responder to gel)
• Cost considerations
• Secondary exposure risk (children, pregnant partner)
• Skin irritation/dermatitis
• Desire for higher testosterone levels
• Inconsistent compliance with daily application

Protocol Selection Summary

Choose Testosterone Gel When:

1. Patient prioritizes stable hormone levels over peak levels
2. Cardiovascular risk factors or elevated baseline hematocrit
3. History of high E2 or gynecomastia on injectable
4. Needle-averse patient
5. Longevity-focused protocol
6. Good insurance coverage or budget for brand products
7. No children or pregnant women in household
8. Consistent daily routine
9. Primary goals are mood, cognition, quality of life
10. Patient willing to follow transfer prevention protocols

Choose Injectable When:

1. Primary goal is muscle hypertrophy
2. Cost is primary concern (generic injectable 5-10x cheaper)
3. Children or pregnant women in household
4. Poor transdermal absorber (5-10% of population)
5. Skin conditions or sensitivity to alcohol-based products
6. Need for higher testosterone levels (>800 ng/dL)
7. Inconsistent daily routine
8. Frequent swimmer or heavy sweater
9. Prefers less frequent dosing

Conclusion

Testosterone gel represents a physiological, convenient testosterone replacement option for men with hypogonadism. The TRAVERSE trial definitively demonstrated cardiovascular safety, leading to removal of the FDA black box warning for CV risk. However, the secondary exposure risk remains a critical safety concern, requiring strict adherence to hand washing, site coverage, and transfer prevention protocols.

Testosterone gel provides sustained, physiological testosterone levels without the "roller-coaster" pharmacokinetics of injectable esters, making it ideal for patients prioritizing steady hormone levels and daily convenience. The lower polycythemia risk compared to injectable testosterone is an additional safety advantage. The transdermal route's unique pharmacokinetics - particularly higher DHT conversion and lower E2 spikes - make it the preferred choice for specific patient profiles.

Clinicians must balance these benefits against higher cost, daily application requirements, skin irritation, and the stringent measures needed to prevent secondary testosterone transfer to women and children. Understanding the gel-specific pharmacokinetics allows for optimized patient selection and protocol customization.

Document Prepared By: Research Team, DosingIQ Original Version: December 2024 Enhanced Version: January 2026 Total Word Count: ~18,000 words Total Citations: 64+ references